SUMOylation, a post-translational modification of intracellular and particularly nuclear proteins, plays a critical role in the response of Acute Myeloid Leukemia (AML) to chemotherapies and differentiation therapies. AMLs are the only hematologic malignancies that have not benefited from a major therapeutic advance during the past 40 years. They are still treated via intensive treatments based on genotoxic agents, with very high fall rates and a poor 5-year survival rate of around 20%. To fill the urgent need for alternative therapies against AML, we are developing new classes of SUMOylation inhibitors using cutting-edge technologies. The Master 2 student that will be recruited on this multidisciplinary project will be in charge of the design and synthesis of peptide inhibitors at the Institut des Biomolécules Max Mousseron (IBMM) and will then evaluate their toxicity, ability to inhibit the SUMOylation and anti-leukemic efficiency at the “Institut de Génétique Moléculaire de Montpellier” (IGMM).
Contacts: firstname.lastname@example.org, email@example.com
6 months internship – starting january-march
Ubiquitin, SUMO, and Nedd8 as Therapeutic Targets in Cancer. Gâtel P, Piechaczyk M, Bossis G. Adv Exp Med Biol. 2020;1233:29-54. doi: 10.1007/978-3-030-38266-7_2.